The Phase 3 EMANATE trial is for individuals with rare forms of obesity caused by genetic variants
A randomized, double-blind, placebo-controlled trial to evaluate setmelanotide in multiple independent sub-studies.
Participants in each sub-study include people 6 to 65 years old with early-onset obesity and hyperphagia who carry certain genetic variants:
- A variant in POMC or PCSK1 genes
- A variant in the LEPR gene
- A variant in the NCOA1 gene
- A variant in the SH2B1 gene